Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | NR1H3 | Q13133 | 7/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.37 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4649466 | 0.74 | POLB (0.65) | POLBNR1H3MEN1KMT2ANR1H2 | |
| SCHEMBL11482027 | 0.73 | NR1H3 (0.51) | POLBNR1H3MEN1KMT2ANR1H2 | |
| SCHEMBL7920276 | 0.72 | CYP3A4 (0.30) | CYP3A4 | |
| SCHEMBL4605071 | 0.71 | MEN1 (0.31) | MEN1KMT2A | |
| SCHEMBL27602812 | 0.70 | POLB (0.47) | POLBNR1H3MEN1KMT2ANR1H2 | |
| SCHEMBL2150841 | 0.70 | MEN1 (0.55) | POLBNR1H3MEN1KMT2ANR1H2 | |
| SCHEMBL1965147 | 0.70 | CYP3A4 (0.33) | CYP3A4 | |
| SCHEMBL1644568 | 0.68 | ALDH1A1 (0.39) | MEN1KMT2AALDH1A1 | |
| SCHEMBL8815712 | 0.67 | POLB (1.00) | POLBNR1H3MEN1KMT2ANR1H2 | |
| SCHEMBL10599476 | 0.67 | ESR1 (0.74) | POLBNR1H3MEN1KMT2ANR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994218-B2 | Simple pantoic acid ester neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use | XENOPORT, INC. (US) | 2011-08-09 | — | — | US | disclosed |
| US-20090082440-A1 | SIMPLE PANTOIC ACID ESTER NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082440-A1 | SIMPLE PANTOIC ACID ESTER NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | ADSL, SLC19A1, SLC25A21 | POLB 2675/4885NR1H3 2066/4885MEN1 1005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.